Unknown

Dataset Information

0

CRISPR-Cas9-mediated gene disruption of HIV-1 co-receptors confers broad resistance to infection in human T cells and humanized mice.


ABSTRACT: In this preclinical study, we evaluated the efficacy and feasibility of creating broad human immunodeficiency virus (HIV) resistance by simultaneously disrupting the human CCR5 and CXCR4 genes, which encode cellular co-receptors required for HIV-1 infection. Using a clinically scalable system for transient ex vivo delivery of Cas9/guide RNA (gRNA) ribonucleoprotein (RNP) complexes, we demonstrated that CRISPR-mediated disruption of CCR5 and CXCR4 in T lymphocyte cells significantly reduced surface expression of the co-receptors, thereby establishing resistance to HIV-1 infection by CCR5 (R5)-tropic, CXCR4 (X4)-tropic, and dual (R5/X4)-tropic strains. Similarly, disruption of CCR5 alleles in human CD34+ hematopoietic stem and progenitor cells (HSPCs) successfully led to the differentiation of HIV-resistant macrophages. In a humanized mouse model under HIV-1 challenge, CXCR4-disrupted CD4+ T cells were enriched in the peripheral blood and spleen, indicating survival advantage because of resistance to viral infection. However, in human CD4+ T cells with both CCR5 and CXCR4 disruption, we observed poor engraftment in bone marrow, although significant changes were not observed in the lung, spleen, or peripheral blood. This study establishes a clinically scalable strategy for the dual knockout of HIV-1 co-receptors as a therapeutic strategy, while also raising caution of disrupting CXCR4, which may abate engraftment of CD4+ T cells in bone marrow.

SUBMITTER: Li S 

PROVIDER: S-EPMC8847835 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

CRISPR-Cas9-mediated gene disruption of HIV-1 co-receptors confers broad resistance to infection in human T cells and humanized mice.

Li Shasha S   Holguin Leo L   Burnett John C JC  

Molecular therapy. Methods & clinical development 20220122


In this preclinical study, we evaluated the efficacy and feasibility of creating broad human immunodeficiency virus (HIV) resistance by simultaneously disrupting the human <i>CCR5</i> and <i>CXCR4</i> genes, which encode cellular co-receptors required for HIV-1 infection. Using a clinically scalable system for transient <i>ex vivo</i> delivery of Cas9/guide RNA (gRNA) ribonucleoprotein (RNP) complexes, we demonstrated that CRISPR-mediated disruption of <i>CCR5</i> and <i>CXCR4</i> in T lymphocyt  ...[more]

Similar Datasets

| S-EPMC8633974 | biostudies-literature
| S-EPMC10440993 | biostudies-literature
| S-EPMC6238604 | biostudies-literature
| S-EPMC6638350 | biostudies-literature
| S-EPMC4612538 | biostudies-literature
| S-EPMC5591563 | biostudies-literature
| S-EPMC5875921 | biostudies-literature
| S-EPMC11772328 | biostudies-literature
| S-EPMC7014288 | biostudies-literature